about
Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteineEffects of aclidinium on determinants of COPD severity: symptoms and quality of lifeOnset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.The evidence on tiotropium bromide in asthma: from the rationale to the bedside.Antileukotrienes in clinical development for asthma.Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitisUnderstanding the burden of pneumococcal disease in adults.A systematic review on tracheostomy decannulation: a proposal of a quantitative semiquantitative clinical score.Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trialAzithromycin and lower respiratory tract infections.Highlights on the appropriate use of fluoroquinolones in respiratory tract infections.How air pollution influences clinical management of respiratory diseases. A case-crossover study in Milan.Pulmonary Rehabilitation in COPD: A Reappraisal (2008-2012)Safety and pharmacological profile of tiotropium bromide.Avoiding misdiagnosis in patients with dyspnea and wheezing: a case report illustrating the clinical implications of fixation error.Budesonide/formoterol dry powder in asthma: an option for control as maintenance and reliever therapy.Anxiety and depression in asthma.Assessing and accessing the small airways; implications for asthma management.Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.Small airway disease in asthma: pathophysiological and diagnostic considerations.Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.Does Improving Exercise Capacity and Daily Activity Represent the Holistic Perspective of a New COPD Approach?Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma.Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease.Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.Epidemiology of clinical trials of medicines in respiratory diseases in Europe and Italy.Disability in moderate chronic obstructive pulmonary disease: prevalence, burden and assessment - results from a real-life study.Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study.Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.Physical activity impairment in depressed COPD subjects.The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD.Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline+fluticasone propionate in patients with COPD.Close correlation between anxiety, depression, and asthma control.Withdrawal of inhaled corticosteroids in COPD: A meta-analysis.
P50
Q26864308-C23F00C2-0826-4365-AAE6-E48FD23DE6DAQ28069533-309F603E-38F1-4FD7-8680-BE2B70B8095FQ31854760-DA92EADF-4FA9-44B6-8612-B732516F593BQ33644971-324C46BE-A19D-469C-8397-145446E917F3Q34481959-323E0875-7B3B-4E0A-AD19-BB23F837AFD8Q34585467-EAC4F8C3-58E0-4AC4-A63E-DE3E2561C5E1Q34641396-D91D60E2-FE06-4DE0-8B1B-0D4965DCFB1EQ34778545-2586DA34-220A-4D91-8A7E-29995753EC7EQ36072399-84E5B317-C843-44AA-9FA6-DCCA67B87586Q36283753-4B0A0B42-59EF-47C2-8E20-9E786A970224Q36323384-77E50073-105F-4FAD-A1E8-7272E1B56C14Q36436703-4A2F9E17-FD47-40AB-83FB-4BDE5B73744EQ36567428-B5AC6B9C-FF32-4B24-B9A2-FCCC7FF73008Q37510963-C87044F0-B5D5-476F-AFDE-CDF95B89850BQ37630817-4EE43BC1-155F-4D97-869B-153506B3D838Q37678433-FDAAC9FC-9F48-4EFF-BA50-88E50D636574Q37803103-54EF36BC-3532-4837-AF61-87582C26E9EEQ38052781-78F2CD5E-BC0A-4F9C-AA49-84C613D7D7A5Q38182303-62C07F4A-D2C6-4873-AB8F-32638C78E775Q38270276-00FCA58D-22E7-4DE9-8657-AE400A43F882Q38274914-8799D42F-F01D-43DE-8AE7-A5AF9D23E889Q38518405-C937D5F6-0A42-4863-B5A1-3057724D7CB1Q38604749-C4D4F031-9269-4751-8992-B6C0B1EC3A4EQ38877581-326DF7C5-686A-4087-872D-A982CE3615D6Q38877990-326B1875-4EC6-47A7-AE18-6E733BEFF883Q38895029-626E8919-DF6D-486D-8241-0BB43DF80ADCQ39462715-BE5F3BD1-AAC1-460B-96F0-D7CB8B09435EQ40052187-E8091749-9CDA-450A-85DA-FD3F01282680Q40274809-EB05387B-5D24-4EBE-B4EB-96026571A0C6Q41542259-B3419DE1-716A-4D36-BBFC-79798F45A93AQ43789380-FCCA412F-0E53-456A-85F9-5847A162C6F2Q43924586-F41D7588-60D5-48BE-B20A-1B4AD03A1C73Q44304488-654AB047-80F8-431A-B239-FC532A1CA418Q44432842-0D9ABE9D-9D83-41E1-BF01-A9586F4F148AQ44463215-8C53285E-A77B-4BE7-BDC5-542649394087Q44672215-7BE3218E-3058-46E5-B79F-038D466FDDEBQ44880652-93C0427F-37AB-44F4-A713-A24E426F0DF9Q44880664-B527B11F-206C-484E-A0AE-D2464B77EC5BQ46134635-CB50AEC0-3E17-4472-8290-7192C6D2028BQ47865046-24684536-0368-4D91-84C1-F91A8DD70AF7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pierachille Santus
@ast
Pierachille Santus
@en
Pierachille Santus
@es
Pierachille Santus
@nl
type
label
Pierachille Santus
@ast
Pierachille Santus
@en
Pierachille Santus
@es
Pierachille Santus
@nl
prefLabel
Pierachille Santus
@ast
Pierachille Santus
@en
Pierachille Santus
@es
Pierachille Santus
@nl
P106
P1153
9247687100
P31
P496
0000-0003-3462-8253